

Application number
2349717

Registration number
TMA1340900

Type(s)
Standard Characters

Category
Trademark

CIPO Status
REGISTERED

TM5 status
LIVE/REGISTRATION/Issued
and Active



The trademark application has
been registered with the Office.

Filed
2024-09-13

Registered
2025-08-15

Registration Expiry Date
2035-08-15

Registered Owner
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285
UNITED STATES OF
AMERICA

Agent
BORDEN LADNER GERVAIS
LLP
World Exchange Plaza
100 Queen Street, Suite 1300
Ottawa
ONTARIO K1P1J9

Documents
[View documents](#)

Index headings

ZOUNDESSA

Goods (Nice class & Statement)

- 5 (1) Pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; pharmaceutical preparations for the prevention and treatment of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for the treatment and prevention of migraines, headaches and pain; pharmaceutical preparations for the treatment and the prevention of dementia; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and bacterial skin infections and fungal skin infections ; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema, and sexually transmitted diseases; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, Crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, ulcerative colitis; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders, and neuromuscular diseases, namely primary periodic paralysis; pharmaceutical preparations for the treatment of endocrine diseases, namely, glucagonoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of immunologic diseases and disorders

namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of mental health disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for treatment of coronavirus;

Claims

Priority Filing Date: April 25, 2024, Country or Office: UNITED STATES OF AMERICA, Application No. 98519677 in association with the same kind of goods

Action History

Action	Action date	Due date	Comments
Filed	2024-09-13		
Created	2024-09-13		
Formalized	2024-09-13		
Pre-Assessment Letter Sent	2024-09-26		Goods or Services Not Acceptable
Search Recorded	2025-03-14		
Approved	2025-03-24		APPROVED BY PROGRAM EX200M1
			APPROVED BY

Approval Notice Sent	2025-03-24		PROGRAM EX200M1
Advertised	2025-05-28		Vol.72 Issue 3683
Registration Pending	2025-08-15		
Registered	2025-08-15	2035-08-15	